![](images/graphics/blank.gif)
Immune-related adverse events
-
Pan-immune-inflammation value (PIV) is defined by the neutrophil, platelet, monocyte, and lymphocyte counts and is associated with immune-checkpoint inhibitor (ICI) therapy outcomes in advanced non-small cell lung cancer (aNSCLC). However, PIV is dynamic under therapy and its longitudinal assessment may help predict efficacy.
11p
visharma
20-10-2023
6
2
Download
-
Infiltrating lymphocytes in the meninges and parenchyma of the brain stem were mainly composed of cluster of differentiation (CD)8-positive lymphocytes. For irAE encephalitis, early recognition of early signs and symptoms and subsequent early therapeutic intervention are necessary. It is important for oncologists to keep in mind of the possible adverse effects of immunotherapies on the nervous system.
7p
viintuit
26-09-2023
5
0
Download
-
Nivolumab is used for the treatment of malignant pleural mesothelioma (MPM). However, immunerelated adverse events (irAEs) occur in patients treated with nivolumab. Several studies have reported the correlation between irAEs and therapeutic efects of immune checkpoint inhibitor, but none have reported the correlation in MPM.
6p
vimackenziebezos
29-11-2021
7
1
Download
-
Immune checkpoint inhibitors (ICI) have become standard treatment in different tumor entities. However, safe treatment with ICI targeting the PD-1/PD-L1 axis requires early detection of immune-related adverse events (irAE).
10p
vianrose2711
27-04-2021
12
2
Download
-
The development and rapid uptake of immune checkpoint inhibitors (CPI) has changed the outlook for patients with cancer. However, CPIs have different adverse event (AE) profiles to other systemic therapies, and prompt AE management is essential to assure optimal outcomes.
11p
vimale2711
21-08-2020
10
0
Download
-
Immune checkpoint blockade is developed as standard treatment for non-small cell lung cancer. However immune-related adverse events (irAE) have still unknown complications. Here, we report a patient with lung squamous cell carcinoma who developed neuromyelitis optica spectrum disorder with nivolumab.
4p
vibaku2711
22-07-2020
13
1
Download
-
Nivolumab is an immune checkpoint inhibitor (ICI) and is used for the treatment of advanced nonsmall cell lung cancer (NSCLC). Several immune-mediated neurological adverse events associated with ICIs have been reported to date, such as Guillain-Barré syndrome.
6p
vikuala271
13-06-2020
6
0
Download
CHỦ ĐỀ BẠN MUỐN TÌM
![](images/graphics/blank.gif)